4556
KAINOS Laboratories,Inc.
カイノス
- Industry
- Pharmaceutical
- Market
- Standard
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2021
4,257,859
Mar 2022
4,614,725
Mar 2023
4,923,246
Mar 2024
5,056,464
Mar 2025
5,305,569
Operating profit(thousand JPY)
Mar 2021
632,301
Mar 2022
747,713
Mar 2023
821,091
Mar 2024
865,212
Mar 2025
823,598
Operating profit margin(%)
Mar 2021
14.85
Mar 2022
16.2
Mar 2023
16.68
Mar 2024
17.11
Mar 2025
15.52
Profit before tax(thousand JPY)
Mar 2021
612,806
Mar 2022
767,124
Mar 2023
845,166
Mar 2024
930,069
Mar 2025
827,155
Profit(thousand JPY)
Mar 2021
417,405
Mar 2022
512,334
Mar 2023
568,174
Mar 2024
637,965
Mar 2025
641,019
Total assets(thousand JPY)
Mar 2021
6,962,332
Mar 2022
7,571,515
Mar 2023
8,115,854
Mar 2024
8,590,984
Mar 2025
8,785,144
Cash and cash equivalents(thousand JPY)
Mar 2021
1,903,770
Mar 2022
2,336,787
Mar 2023
2,679,848
Mar 2024
2,833,883
Mar 2025
3,056,322
Cash flows from operating activities(thousand JPY)
Mar 2021
591,249
Mar 2022
604,363
Mar 2023
544,510
Mar 2024
430,578
Mar 2025
704,782
Cash flows from investing activities(thousand JPY)
Mar 2021
-117,163
Mar 2022
-141,187
Mar 2023
-10,328
Mar 2024
-72,828
Mar 2025
-71,304
Cash flows from financing activities(thousand JPY)
Mar 2021
-194,611
Mar 2022
-31,255
Mar 2023
-191,136
Mar 2024
-203,726
Mar 2025
-411,037
Return on equity(%)
Mar 2021
9.2
Mar 2022
10.4
Mar 2023
10.5
Mar 2024
10.7
Mar 2025
9.8
Equity ratio(%)
Mar 2021
66.9
Mar 2022
68.7
Mar 2023
69.9
Mar 2024
72.9
Mar 2025
77.1
Earnings per share(JPY per share)
Mar 2021
100.63
Mar 2022
126.39
Mar 2023
136.13
Mar 2024
152.26
Mar 2025
152.06
Net assets per share(JPY per share)
Mar 2021
1,138.21
Mar 2022
1,245.93
Mar 2023
1,358.35
Mar 2024
1,486.43
Mar 2025
1,607.15
Dividend per share(JPY per share)
Mar 2021
15
Mar 2022
25
Mar 2023
25
Mar 2024
32
Mar 2025
35
Payout ratio(%)
Mar 2021
14.91
Mar 2022
19.78
Mar 2023
18.36
Mar 2024
21.02
Mar 2025
23.02
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.